Rajnish Wellness Ltd (RAJNISH)

About

Rajnish Wellness Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹1

Market cap

₹37 Cr

P/E

—

P/B

0.4×

Dividend yield

0%

ROE

-6.7%

ROCE

-8.8%

Debt / equity

0

OPM

-6.5%

EPS (TTM)

₹-0.1

Book value

₹1.0

52-week high

—

52-week low

—

915 historical price candles were omitted because the exchange source has not been verified.

₹0.4-5.3%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 60.4% over the last 5 years
+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -1.8% (3-yr avg)
−Low promoter holding of 9.2%

Research score

Structured signal from quality, growth, valuation and momentum.

75/100

Business quality: 25
Growth: 100
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	13	26	26	77	49	142
COGS	15	24	23	71	46	138
Gross profit	-2	2	3	6	3	4
	1	3	4	4	3	13
	-3	-0	-1	2	0	-9
OPM %	-23.8%	-0.7%	-4.3%	2.6%	0%	-6.5%
Depreciation	0	0	0	0	0	0
Interest	0	0	0	1	0	0
	4	1	2	0	1	1
Profit before tax	0	0	1	1	0	-8
Tax	0	0	0	0	0	-2
Tax %	16.7%	14.9%	27%	28.3%	26.1%	-25.3%
	0	0	0	1	0	-6
PAT margin %	0.8%	1.5%	1.8%	1.3%	0.4%	-4.4%
EPS (₹)	—	—	—	—	—	0.1
EPS adjusted (₹)	0	0	0	0	0	-0.1
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	5	11	77	77	77	102
Reserves	17	12	6	7	7	1
Minority interest	0	—	—	—	—	—
	9	0	0	1	0	0
	4	13	16	21	7	6
Total equity & liabilities	35	35	99	106	91	109
	0	0	0	0	0	0
CWIP	—	—	—	—	—	0
Investments	0	0	0	0	0	8
	35	35	99	106	91	101
Total assets	35	35	99	106	91	109

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	-0	-62	2	-4	-9
	0	-0	-0	-0	9	-7
	-0	1	62	-2	-5	25
Net cash flow	0	1	-1	-0	0	9
Free cash flow	0	—	—	2	-4	-9
CFO / Operating profit %	—	—	—	86.3%	—	—

Compounded sales growth

7 years: —
5 years: 60%
3 years: 76%
1 year: 192%

Return on equity

7 years: —
5 years: -1%
3 years: -2%
Last year: -6%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	-13.3%	9.3%	10.5%	7.4%	5.8%	2.7%
EBITDA margin %	-23.8%	-0.7%	-4.3%	2.6%	0%	-6.5%
EBIT margin %	-24.2%	-0.7%	-4.3%	2.5%	-0%	-6.5%
PAT margin %	0.8%	1.5%	1.8%	1.3%	0.4%	-4.4%
Working capital
Receivable days	460	224	285	160	201	50
Inventory days	27	32	59	48	79	35
Payable days	50	17	55	78	30	0
NWC days	436	238	289	130	249	85
Leverage
Current ratio	2.65	8.63	6.58	4.86	16.78	25.12
Debt to EBITDA	—	—	—	0.6	—	—
Debt to equity	0.4	0	0	0.01	0	0
Interest coverage	1.4	2.6	16.7	3.8	1.9	—
Asset turnover	0.39	0.75	0.26	0.72	0.53	1.31
Return ratios
Return on assets %	0.3%	1.1%	0.5%	1%	0.2%	-5.8%
Return on capital employed %	1.9%	2.8%	1.1%	2.1%	0.6%	-8.8%
Return on equity %	0.5%	1.8%	0.6%	1.2%	0.2%	-6.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	16.24%	16.24%	16.24%	16.24%	16.24%	7.41%	7.41%	7.41%	9.16%	9.16%	9.16%	9.16%
	0%	0%	1.09%	1.2%	0.2%	0%	0.57%	0.57%	0.43%	0.43%	0.43%	0.43%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	83.76%	83.76%	82.67%	82.56%	83.56%	92.59%	92.02%	92.02%	90.41%	90.41%	90.41%	90.41%
No. of shareholders	—	—	—	—	—	—	—	—	1,65,636	1,62,955	1,60,259	1,58,442

Promoter holding down 7.08 percentage points since Sep 2023.

307 deals · 10 Aug 2021 – 30 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Jun 2026	RIKANT PITTIE	Bulk	BSE	Sell	66,80,000	₹0.41	₹0.27 Cr
7 May 2026	JASMITSINGHCHANDHOK	Bulk	BSE	Sell	76,00,000	₹0.45	₹0.34 Cr
6 May 2026	JASMITSINGHCHANDHOK	Bulk	BSE	Sell	1,06,80,378	₹0.47	₹0.50 Cr
12 Mar 2026	JASMITSINGHCHANDHOK	Bulk	BSE	Buy	65,56,610	₹0.52	₹0.34 Cr
23 Jan 2026	SAROJ KUMAR KUNDU	Bulk	BSE	Sell	54,27,229	₹0.48	₹0.26 Cr
13 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Sell	56,21,170	₹0.51	₹0.29 Cr
13 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	50,65,286	₹0.52	₹0.26 Cr
12 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Buy	72,70,069	₹0.51	₹0.37 Cr
12 Jan 2026	SHARE INDIA SECURITIES LIMITED	Bulk	BSE	Sell	62,20,069	₹0.50	₹0.31 Cr
26 Dec 2025	RAJPUT RAVINDRA B	Bulk	BSE	Sell	75,00,000	₹0.54	₹0.41 Cr

1–10 of 307

1 / 31

Mr. RAJNISHKUMAR SURENDRAPRASAD SINGHExecutive Director-Chairperson-MD
Ms. MONAM KAPOORNon-Executive - Independent Director
Ms. PREETINon-Executive - Independent Director
Ms. SWATI JAINNon-Executive - Independent Director
Ms. SALONI MEHRANon-Executive - Non Independent Director
Mihir Shrenik PatwaChief Financial Officer
Ms. Anupma KashyapCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Rajnish Wellness Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

10

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results13 Aug 2026

2

Face value ₹2 → ₹110 Jan 2023 · ex-date
Face value ₹10 → ₹221 Jul 2022 · ex-date

2

Bonus 2:121 Jul 2022 · ex-date
Bonus 5:423 Dec 2021 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

14 announcementsExport CSV

28 Sept 2026, 8:24 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

28 Sept 2026, 1:10 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

5 Sept 2026, 5:50 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

5 Sept 2026, 12:36 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

4 Sept 2026, 4:29 pmCompany Update

Intimation Related To Shareholders Whose Email Is Not Registered With RTA

General PDF

4 Sept 2026, 4:19 pmCorp. Action

Intimation Related To Book Closure For The Purpose Of AGM

Book Closure PDF

4 Sept 2026, 4:12 pmAGM/EGM

Notice Of The 11Th Annual General Meeting Of The Company Scheduled To Be Held Through VC/OAVM On Saturday The 26Th September, 2026

AGM PDF

4 Sept 2026, 4:05 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

Date	Category	Subject	Filing
28 Sept 2026, 8:24 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
28 Sept 2026, 1:10 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF

Loading announcements…

Rajnish Wellness Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Stock splits2

Bonus issues2

Announcements

Not in the F&O segment

Quarterly record

Bulk & block deals

Board and management

Board meetings1

Stock splits2

Bonus issues2

Ratio timeline

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

2

2

1

2

2